Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution

Mashup Score: 1

Journal of the American Academy of Dermatology - To the Editor: It has become increasingly recognized that JAK inhibitors (JAKis) have substantial efficacy in the treatment of alopecia areata (AA).1 JAKis approved by the US Food and Drug Administration (FDA) are currently under patent in the United States and can be expensive. The high cost of medication is a significant obstacle for patients, and, in the United States, the vast majority rely...

Read the full article here

Related Content